Abstract
Nonalcoholic fatty liver disease (NAFLD) is one of the most frequent metabolic chronic liver diseases in developed countries and puts the populations at risk of progression to liver necro-inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma. Mitochondrial dysfunction is involved in the onset of NAFLD and contributes to the progression from NAFLD to nonalcoholic steatohepatitis (NASH). Thus, liver mitochondria could become the target for treatments for improving liver function in NAFLD patients. This chapter describes the most important steps used for potential therapeutic interventions in NAFLD patients, discusses current options gathered from both experimental and clinical evidence, and presents some novel options for potentially improving mitochondrial function in NAFLD.
Keywords:
Fatty liver; Mitochondria; Nitrosative stress; Nonalcoholic fatty liver disease; Oxidative stress.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Anti-Inflammatory Agents / adverse effects
-
Anti-Inflammatory Agents / therapeutic use*
-
Antioxidants / adverse effects
-
Antioxidants / therapeutic use*
-
Apoptosis / drug effects
-
Humans
-
Hypoglycemic Agents / adverse effects
-
Hypoglycemic Agents / therapeutic use*
-
Inflammation Mediators / metabolism
-
Liver / drug effects*
-
Liver / metabolism
-
Liver / pathology
-
Liver Cirrhosis / drug therapy*
-
Liver Cirrhosis / metabolism
-
Liver Cirrhosis / pathology
-
Mitochondria, Liver / drug effects*
-
Mitochondria, Liver / metabolism
-
Mitochondria, Liver / pathology
-
Non-alcoholic Fatty Liver Disease / drug therapy*
-
Non-alcoholic Fatty Liver Disease / metabolism
-
Non-alcoholic Fatty Liver Disease / pathology
-
Oxidative Stress / drug effects
-
Risk Reduction Behavior
Substances
-
Anti-Inflammatory Agents
-
Antioxidants
-
Hypoglycemic Agents
-
Inflammation Mediators